M
Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA.
Investor insights
Funding rounds participated in
$400M sweet spot round size
Investor type
Privately Held
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
2024
Funding rounds raised
Total raised
$400M
from 2 investors over 1 rounds
M
Mirador Therapeutics raised $400M on April 21, 2024
Investors: ARCH Venture Partners and + 15 Other investors